Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of pharmaceutical composition and its application

A composition and drug technology, applied in the field of traditional Chinese medicine, can solve the problems of patients’ pain and high price, and achieve the effect of good curative effect, high safety and growth inhibition

Inactive Publication Date: 2016-08-17
THE FIFTH MEDICAL CENT OF CHINESE PLA GENERAL HOSPITAL
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These treatments are not only expensive, but the treatment process often brings great pain to patients
For example, sorafenib, a targeted drug for advanced liver cancer recognized at home and abroad, costs more than 100,000 yuan a year, and prolongs the life of the patient for only a few months. At the same time, it may be accompanied by diarrhea, rash, high blood pressure, etc serious adverse reaction

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of pharmaceutical composition and its application
  • A kind of pharmaceutical composition and its application
  • A kind of pharmaceutical composition and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Example 1: The preparation of pharmaceutical composition of the present invention:

[0037] According to the weight ratio between juglandin B and icariin is 1:1, the raw materials are weighed, and the two are mixed evenly to obtain the pharmaceutical composition of the present invention.

[0038] The application of the combined medicine of juglandrin B and icariin, that is, the pharmaceutical composition of the present invention (jugandrin B+icariin) in the treatment of liver cancer will be further described below in conjunction with specific experimental examples.

[0039] 1. Experimental materials:

[0040] 1. Drugs and reagents:

[0041] The extraction method of Juglanin B refers to the article "Isolation of Juglanin B in Beiqinglongyi and Establishment of Content Determination Method" published by Liu Lijuan et al. on pages 46-48 of "Chinese Modern Applied Pharmacy". All icariin was purchased from Shanghai Yuanye Biotechnology Co., Ltd., and the production batch...

experiment example 1

[0049] Experimental example 1: The effect of each administration group on the human liver cancer cell line HepG2 was detected by MTT method:

[0050] The HepG2 cell line was cultured, and when the cells grew to 50-60% confluence, the subjects were divided into 4 groups, namely the Juglandin B group, the Icaritin group, the Juglandin B+Icaritin group and the control group. Correspondingly add 200 μg / mL juglandin B, 200 μg / mL icariin, pharmaceutical composition of the present invention (wherein juglandin B 200 μg / mL+icariin 200 μg / mL) and dissolve in the culture solution of each group 100 μL of DMSO (dimethyl sulfoxide) used for the compound. Cells were cultured for 24 hours, and cell viability was measured using the MTT assay. The method is as follows: remove the supernatant, wash twice with phosphate buffered saline (PBS), incubate with MTT at 37°C for 4 hours, wash twice with PBS, dissolve the crystals with DMSO, measure the absorbance at 490nm, and calculate the growth in...

experiment example 2

[0056] Experimental example 2: MTT assay was used to detect the effect of each administration group on the mouse hepatoma cell line H 22 Impact:

[0057] culture H 22 Cell line, when the cells grow to 50-60% confluence, the subjects are divided into 4 groups, ie juglandin B group, icariin group, juglandin B+icariin group and control group. Correspondingly add 200 μg / mL juglandin B, 200 μg / mL icariin, pharmaceutical composition of the present invention (wherein juglandin B 200 μg / mL+icariin 200 μg / mL) and dissolve in the culture solution of each group 100 μL of DMSO (dimethyl sulfoxide) used for the compound. Cells were cultured for 24 hours, and cell viability was measured using the MTT assay. The method is as follows: remove the supernatant, wash twice with phosphate buffered saline (PBS), incubate with MTT at 37°C for 4 hours, wash twice with PBS, dissolve the crystals in DMSO, and measure the absorbance at 570 nm.

[0058]

[0059] The experimental results are show...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition and its application, belonging to the technical field of traditional Chinese medicine. The pharmaceutical composition is composed of juglandin B and icariin in a weight ratio of 1:1. The invention also discloses the application of the pharmaceutical composition in the preparation of medicines for treating liver cancer. The invention has the advantages of simple preparation, good curative effect, no side effect, high safety, is helpful for patients to relieve symptoms in time, has good development prospects and social and economic benefits.

Description

technical field [0001] The invention belongs to the technical field of traditional Chinese medicine, and in particular relates to a pharmaceutical composition and its application. Background technique [0002] Primary hepatic carcinoma (PHC), referred to as liver cancer for short, refers to malignant tumors that originate in liver cells or intrahepatic bile duct epithelial cells, and is known as the "king of tumors". Its death rate ranks fifth in the world and third in my country. According to the statistics of the World Health Organization, before 2030, liver cancer will continue to grow, and its mortality rate will rank second. [0003] At present, there is no good treatment for advanced liver cancer in China. Traditional treatment methods include surgery, radiotherapy, chemotherapy and interventional therapy. These treatment methods are not only expensive, but also often bring great pain to patients during the treatment process. For example, Sorafenib, a targeted drug...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/7034A61P35/00A61K31/352
Inventor 赵艳玲肖小河王伽伯陈哲郑全福
Owner THE FIFTH MEDICAL CENT OF CHINESE PLA GENERAL HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com